ImportRefusal LogoImportRefusal

SRI Krishna Pharmaceuticals Ltd - Unit I

⚠️ Moderate Risk

FEI: 3003723117 • Hyderabad, Telangana • INDIA

FEI

FEI Number

3003723117

📍

Location

Hyderabad, Telangana

🇮🇳

Country

INDIA
🏢

Address

C - 4 Industrial Area, Medchal - Malkajgiri; Uppal Khalsa, Hyderabad, Telangana, India

Moderate Risk

FDA Import Risk Assessment

39.9
LowModerateHighCritical

This firm has a moderate history of FDA import refusals. Some attention may be warranted.

Statistics

12
Total Refusals
3
Unique Violations
2/2/2015
Latest Refusal
5/15/2003
Earliest Refusal

Score Breakdown

Violation Severity
66.3×40%
Refusal Volume
41.3×30%
Recency
0.0×20%
Frequency
10.2×10%
How is this score calculated?

Proprietary Algorithm

  • 40% Violation Severity — AI-assessed (1-10)
  • 30% Refusal Volume — Logarithmic scale
  • 20% Recency — Decays over 5 years
  • 10% Frequency — Refusals per year

© ImportRefusal.com Original Analysis

Violation Summary

167×

DIRECTIONS

The article is subject to refusal of admission pursuant to section 801(a)(3) in that it is a device whose label appears to not bear adequate directions for use.

1186×

NOT LISTED

It appears the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by section 510(j) or 510(k).

753×

UNAPPROVED

The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA).

Refusal History

DateProductViolationsDivision
2/2/2015
62GBA41IBUPROFEN (ANTI-INFLAMMATORY)
75UNAPPROVED
Florida District Office (FLA-DO)
6/20/2014
61FCA55CIPROFLOXACIN HYDROCHLORIDE (ANTI-BACTERIAL PART I) (NOT ANTIBIOTIC)
118NOT LISTED
Florida District Office (FLA-DO)
6/5/2014
62GBA41IBUPROFEN (ANTI-INFLAMMATORY)
75UNAPPROVED
Division of Southeast Imports (DSEI)
3/12/2014
61TAB31DOMPERIDONE
118NOT LISTED
Division of Southeast Imports (DSEI)
9/13/2007
60LBS99ANALGESIC, N.E.C.
16DIRECTIONS
New York District Office (NYK-DO)
8/7/2006
60LAS01ACETAMINOPHEN (ANALGESIC)
118NOT LISTED
16DIRECTIONS
New York District Office (NYK-DO)
6/12/2006
66VCS99MISCELLANEOUS PATENT MEDICINES, ETC.
118NOT LISTED
16DIRECTIONS
New York District Office (NYK-DO)
1/27/2006
60LDS01ACETAMINOPHEN (ANALGESIC)
118NOT LISTED
Chicago District Office (CHI-DO)
1/12/2005
64HAS02GUAIFENESIN (EXPECTORANT)
118NOT LISTED
16DIRECTIONS
New York District Office (NYK-DO)
9/27/2004
61TCS99ANTI-EMETIC/NAUSEANT N.E.C.
16DIRECTIONS
Atlanta District Office (ATL-DO)
9/9/2004
60LAS01ACETAMINOPHEN (ANALGESIC)
16DIRECTIONS
New York District Office (NYK-DO)
5/15/2003
61TCR12METOCLOPRAMIDE HCL (ANTI-EMETIC/NAUSEANT)
16DIRECTIONS
75UNAPPROVED
Southwest Import District Office (SWI-DO)

Frequently Asked Questions

What is SRI Krishna Pharmaceuticals Ltd - Unit I's FDA import refusal history?

SRI Krishna Pharmaceuticals Ltd - Unit I (FEI: 3003723117) has 12 FDA import refusal record(s) in our database, spanning from 5/15/2003 to 2/2/2015.

What is an FEI number?

FEI stands for Firm Establishment Identifier. It's a unique number assigned by the FDA to identify establishments that manufacture, process, pack, or hold food, drugs, medical devices, or other FDA-regulated products. SRI Krishna Pharmaceuticals Ltd - Unit I's FEI number is 3003723117.

What types of violations has SRI Krishna Pharmaceuticals Ltd - Unit I received?

SRI Krishna Pharmaceuticals Ltd - Unit I has been cited for 3 different violation type(s). Common FDA violations include adulteration (unsafe or unsanitary products), misbranding (incorrect or misleading labels), and regulatory non-compliance.

Where does this information about SRI Krishna Pharmaceuticals Ltd - Unit I come from?

All FDA import refusal data for SRI Krishna Pharmaceuticals Ltd - Unit I is sourced from the official FDA Data Dashboard (datadashboard.fda.gov), a public government database maintained by the U.S. Food and Drug Administration.

Data sourced from the FDA Data Dashboard, a public database maintained by the U.S. Food and Drug Administration.